Navigation Links
An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes

ttings. There are no contraindications for JANUVIA.

Sitagliptin is also a component of JANUMET(TM) (sitagliptin/metformin HCl), the first and only tablet combining a DPP-4 inhibitor and metformin for the treatment of type 2 diabetes. JANUMET is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes who are not adequately controlled on metformin or sitagliptin alone or in patients already being treated with the combination of sitagliptin and metformin. Consistent with the labeling for metformin alone, JANUMET is contraindicated in patients with renal disease, renal dysfunction, or abnormal creatinine clearance; and acute or chronic metabolic acidosis, including diabetic ketoacidosis. JANUMET should not be used in patients with type 1 diabetes. Consistent with the labeling for metformin alone, the labeling for JANUMET contains a boxed warning for lactic acidosis, a rare, but serious, metabolic complication that can occur due to metformin accumulation during treatment.

Investigational use of JANUVIA and metformin as initial combination therapy led to improvement in markers of beta cell function in patients with type 2 diabetes (0533-P; Study #036)

In this investigational study, the effects of JANUVIA and metformin on beta cell function were examined in patients with type 2 diabetes who participated in a 24-week, placebo-controlled study in which 1,091 patients were randomized to one of six treatments: JANUVIA 50 mg/metformin 1000 mg twice daily (n=182); JANUVIA 50 mg/metformin 500 mg twice daily (n=190); metformin 1000 mg twice daily (n=182); metformin 500 mg twice daily (n=182); JANUVIA 100 mg once-daily (n=179); or placebo (n=176). Of these, a subset of 500 patients underwent frequently sampled meal tolerance tests. Beta cell function was measured using a computer model based evaluation. Parameters of beta cell function from this model allowed for the estimation of the insulin secretion r
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
3. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
4. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
5. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
6. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
7. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
10. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
11. Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents With Schizophrenia
Post Your Comments:
(Date:7/28/2014)... July 28, 2014 Concord Medical Services Holdings ... CCM ), a leading specialty hospital management solution provider ... diagnostic imaging centers in China , ... of Directors declared a special cash dividend of US$0.30 ... ("ADS")) on the Company,s outstanding ordinary shares. The total ...
(Date:7/28/2014)... July 28, 2014 ... 2,5 Millionen £ investiert hat, um die ... Gesundheits-, Pharma- und Logistikbranche zu erfüllen. Albion ...      (Photo: http://photos.prnewswire.com/prnh/20140728/697982 ) ... OmPrompt sein beschleunigtes Wachstum mit Investitionen in ...
(Date:7/28/2014)... NEW PROVIDENCE, N.J. , July 28, 2014 /PRNewswire/ ... meet with Linde,s Healthcare division experts at the ... at McCormick Place in Chicago, Illinois ... nothing less than complete confidence in a reliable medical ... Segment manager. "Linde understands the importance of this critical ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2OmPrompt erhält Finanzierung für Marktexpansion von Kundenautomatisierungsmanagement 2Linde's Healthcare division to display new Hospital Services platform at the national ASHE Conference in Chicago 2
... Ill. and LONDON, Sept. 23 Following today’s announcements ... the European Medicines Agency (EMA) for rosiglitazone in the ... Takeda Pharmaceuticals Europe Limited (“Takeda”) underscore the company’s commitment ... and to the millions of people living with type ...
... Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two ... of 1,800 Real-World Patients Compared XIENCE V to the Newer-Generation TAXUS® Liberte®,-- ... Performance in Key Safety and Efficacy... -- ABBOTT PARK, Ill., Sept. 23 ... ...
Cached Medicine Technology:Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 2Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 3Takeda Responds to Announcement about Suspension of Rosiglitazone Marketing Authorization in Europe and Restrictions in the U.S. 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 2Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 3Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 4Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 5Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 6Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 7Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 8Abbott's XIENCE V® Shows Continued Strong Performance in Key Safety and Efficacy Measures at Two Years in Investigator-Initiated COMPARE Trial 9
(Date:7/28/2014)... 28, 2014 Thousands of DePuy Pinnacle ... of individuals who were allegedly injured by a metal-on-metal ... move forward in U.S. District Court, Northern District of ... issued on July 18, 2014, U.S. District Judge Ed ... the Plaintiffs’ Steering Committee that sought the deposition of ...
(Date:7/28/2014)... Braintree, Massachusetts (PRWEB) July 28, 2014 ... the Summit Provider Exchange technology solution ... office integration efforts and support collaboration with their ... 242 bed acute-care medical center located in New ... 800,000 seasonal visitors with a variety of inpatient ...
(Date:7/28/2014)... July 28, 2014 (HealthDay News) --,The more chronic medical ... life expectancy may be, a new study claims. ... multiple health issues, scientists at Johns Hopkins Bloomberg School ... help explain why gains in life expectancy are slowing ... diseases such as diabetes, kidney disease and heart failure ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, 2014 ... irregularities are more likely to get a pacemaker than people ... study of more than 16,000 people found that those with ... a pacemaker than those without the memory-robbing condition. ... dementia are so much more likely to be treated with ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Parker Waichman LLP, ... fighting to ensure that the heroes of 9/11 are never ... has announced an important deadline. According to a VCF ... with a covered cancer on or before October 12, 2012 ... 2014. First responders and others who were allegedly injured by ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 2Health News:Cape Regional Medical Center Chooses Summit Provider Exchange to Connect With NJSHINE and Physician Offices 3Health News:Chronic Medical Conditions Can Shorten Seniors' Lives: Study 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3
... and Fertilisers and Steel Ramvilas Paswan announced that central ... India//, in order to promote and encourage studies and ... Friday that his ministry would set up four new ... Pharmaceutical Education and Research (NIPER) in Hajipur in Bihar, ...
... Johnstone, 28, was suffering from Deep Vein Thrombosis since four ... after doctors told her that she no longer suffered Deep ... blood clot that had formed in her legs moved up ... lungs. ,Kathy and Norman, Karen’s parents, absolutely devastated are ...
... Omega-3 fish oil capsules could boost the brainpower of youngsters ... Newhall Park Primary School in Bradford, Britain, gave a daily ... between eight and nine for about nine months and found ... of Daily Mail. ,According to the study, 74 ...
... plans to spend in this financial year $21 billion ... doubts on whether this enormous expenditure is paying off, ... the expenditure is paying off and is more successful ... is now available on line is due to be ...
... A Government official reports, ‘Indonesia hasn’t shared the genetic information ... of disease control and environment, Nyoman Kandun//, at the Indonesian ... considered and discussed by the Government before any public release ... has been used for research purpose. ,A chain ...
... have fallen by 6,000 in the last year.,Previous results show ... last year//. But this year it reveals a steep fall ... months – says Health Minister Paul Goggins. ,He ... and he assures that necessary steps will be taken to ...
Cached Medicine News:Health News:New Study Conducted To Evaluate The Success Of The Federal governments Funds For HIV/AIDS 2
Binocular indirect ophthalmic lenses. General diagnosis & treatment....
Binocular indirect ophthalmic lenses. Ultra-High resolutions viewing of posterior pole....
... super series slit ... Variable retinal scanning ... fundus diagnostic capability, ... potential field of ...
Volk indirect lenses. Wide field retinal diagnosis & treatment....
Medicine Products: